Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 8, 354

New Frontiers in the Pathobiology and Treatment of Cancer Regimen-Related Mucosal Injury


New Frontiers in the Pathobiology and Treatment of Cancer Regimen-Related Mucosal Injury

Marika Cinausero et al. Front Pharmacol.


Mucositis is a common complication of chemotherapy, radiotherapy and targeted agents. It often affects compliance to anticancer therapies as it frequently causes schedule delays, interruptions or discontinuations of treatment. Moreover, the economic impact related to the management of mucositis is topical and several estimations of additional hospital costs due to this clinical condition have been recently reported. The ability to determine risk factors for mucositis, to early detect its onset, to assess correctly the degree of this toxicity and to plan its multidisciplinary management are all key elements to guarantee the quality of life of patients and to avoid useless dose reduction or interruption of treatment. The pathogenesis of mucositis is multifactorial and it is classily subdivided into oral and gastrointestinal mucositis according to its anatomic presentation. Treatment and patients' related factors might help in predicting the frequency and the potential degree of symptoms onset. Here we discuss about clinical presentation and pathogenesis of mucositis in relation to different kinds of treatments. Moreover, we focus on therapeutic and prevention strategies, describing past and present management according to international guidelines and the most promising new data about agents potentially able to further improve the treatment of mucositis in the next future.

Keywords: anticancer treatment; gastrointestinal mucositis; management; oral mucositis; pathobiology.


Pathobiology of mucositis. With permission of Sonis (2007). “Reprinted with permission from Frontline Medical Communications, Inc.”

Similar articles

See all similar articles

Cited by 12 PubMed Central articles

See all "Cited by" articles


    1. Abayomi J., Kirwan J., Hackett A. (2009). The prevalence of chronic radiation enteritis following radiotherapy for cervical or endometrial cancer and its impact on quality of life. Eur. J. Oncol. Nurs. 13 262–267. 10.1016/j.ejon.2009.02.007 - DOI - PubMed
    1. Abdel-Rahman O., ElHalawani H., Essam-Eldin S. (2016). S-1-based regimens and the risk of oral and gastrointestinal mucosal injury: a meta-analysis with comparison to other fluoropyrimidines. Expert Opin. Drug Saf. 15 5–20. 10.1517/14740338.2016.1105959 - DOI - PubMed
    1. Abdel-Rahman O., Fouad M. (2015). Risk of oral and gastrointestinal mucosal injury in patients with solid tumors treated with everolimus, temsirolimus or ridaforolimus: a comparative systematic review and meta-analysis. Expert Rev. Anticancer Ther. 15 847–858. 10.1586/14737140.2015.1047350 - DOI - PubMed
    1. Adebahr S., Schimek-Jasch T., Nestle U., Brunner T. B. (2016). Oesophagus side effects related to the treatment of oesophageal cancer or radiotherapy of other thoracic malignancies. Best Pract. Res. Clin. Gastroenterol. 30 565–580. 10.1016/j.bpg.2016.07.003 - DOI - PubMed
    1. Ala S., Saeedi M., Janbabai G., Ganji R., Azhdari E., Shiva A. (2016). Efficacy of sucralfate mouth wash in prevention of 5-fluorouracil induced oral mucositis: a prospective, randomized, double-blind, controlled trial. Nutr. Cancer 68 456–463. 10.1080/01635581.2016.1153666 - DOI - PubMed